{"product_id":"drug-discrimination-9780470433522","title":"Drug Discrimination","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eAlthough somewhat labor intensive, Drug Discrimination (DD) is of enormous applicability to the understanding of drug action.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cb\u003ePreface xv\u003c\/b\u003e  \u003cp\u003e\u003cb\u003eContributors xix\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart I 1\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eRichard A. Glennon and Richard Young\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1. An Introduction to Drug Discrimination 3\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eA. General Scope and Introductory Comments 3\u003c\/p\u003e \u003cp\u003eB. Background and Utility of the Drug Discrimination Paradigm 7\u003c\/p\u003e \u003cp\u003eC. Drug Discrimination: A Synopsis of the Approach 10\u003c\/p\u003e \u003cp\u003eD. Drug Discrimination and Drugs of Abuse 11\u003c\/p\u003e \u003cp\u003eE. Advantage of the Drug Discrimination Procedure 14\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2. Methodological Considerations 19\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eA. Apparatus 19\u003c\/p\u003e \u003cp\u003eB. Subjects 22\u003c\/p\u003e \u003cp\u003eC. Operant Conditioning 23\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3. Drug Discrimination: Practical Considerations 41\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eA. Drugs as Discriminative Stimuli 42\u003c\/p\u003e \u003cp\u003eB. Choice of Dose and Pre-session Injection Interval 49\u003c\/p\u003e \u003cp\u003eC. Discrimination Training Procedure 51\u003c\/p\u003e \u003cp\u003eD. Discrimination Data 52\u003c\/p\u003e \u003cp\u003eE. Testing 60\u003c\/p\u003e \u003cp\u003eF. Data Analysis and Interpretations 78\u003c\/p\u003e \u003cp\u003eG. Selected Topics 99\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4. Role of Stereochemistry in Drug Discrimination Studies 129\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eA. Structural Isomers: Introduction 129\u003c\/p\u003e \u003cp\u003eB. Constitutional Isomers 130\u003c\/p\u003e \u003cp\u003eC. Stereoisomers 136\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5. Drug Discrimination and in Vivo Structure-Activity Relationships 163\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eA. Structure-Activity Caveats 163\u003c\/p\u003e \u003cp\u003eB. Phenylalkylamines Hallucinogens and Stimulants 165\u003c\/p\u003e \u003cp\u003eC. Benzodiazepines 175\u003c\/p\u003e \u003cp\u003eD. Neuronal Nicotinic Acetylcholinergic receptor Agents 177\u003c\/p\u003e \u003cp\u003eE. Aminotetralins 178\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6. Drug Discrimination and Mechanisms of Drug Action 183\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eA. Early Considerations 184\u003c\/p\u003e \u003cp\u003eB. Classical Hallucinogens 186\u003c\/p\u003e \u003cp\u003eC. Amphetamine-Related Stimulants 192\u003c\/p\u003e \u003cp\u003eD. MDA and MDMA 198\u003c\/p\u003e \u003cp\u003eE. PMMA 204\u003c\/p\u003e \u003cp\u003eF. a-Ethyltryptamine 205\u003c\/p\u003e \u003cp\u003eG. Anxiolytic Agents 206\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7. Drug Discrimination and Development of Novel Agents and Pharmacological Tools 217\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eA. Applicability and General Comments 217\u003c\/p\u003e \u003cp\u003eB. Novel 5-HT\u003csub\u003e2\u003c\/sub\u003e Serotonin Receptor Antagonists 218\u003c\/p\u003e \u003cp\u003eC. 5-HT\u003csub\u003e2\u003c\/sub\u003e Serotonin Receptor Agonists and Radioligands 222\u003c\/p\u003e \u003cp\u003eD. Aminotetralins as 5-HT\u003csub\u003e1A\u003c\/sub\u003e Serotonin Receptor Ligands 225\u003c\/p\u003e \u003cp\u003eE. Arylpiperazine 5-HT\u003csub\u003e1A\u003c\/sub\u003e Serotonin Receptor Antagonists 225\u003c\/p\u003e \u003cp\u003eF. MD-354 (\u003ci\u003emeta\u003c\/i\u003e-Chlorophenylguanidine): A 5-HT\u003csub\u003e3\u003c\/sub\u003e Serotonin Receptor Agonist 227\u003c\/p\u003e \u003cp\u003eG. Loperamide and Risperidone: Clinical Successes 230\u003c\/p\u003e \u003cp\u003e\u003cb\u003eAppendix 235\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart II 239\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8. Perceptual Drug Discriminative Aspects of the Endocannabinoid Signaling System in Animals and Man 241\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eTorbjörn U. C. Järbe\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eA. Introduction 242\u003c\/p\u003e \u003cp\u003eB. Brief Synopsis of the Endocannabinoid Signaling System (ECS) 243\u003c\/p\u003e \u003cp\u003eC. Cannabinoids\/Cannabinergics and Drug Discrimination 244\u003c\/p\u003e \u003cp\u003eD. Experimental Procedures and Species 244\u003c\/p\u003e \u003cp\u003eE. Training Drugs 247\u003c\/p\u003e \u003cp\u003eF. Procedural Considerations 253\u003c\/p\u003e \u003cp\u003eG. Intended and Unintended “Bias” in Drug Discrimination 254\u003c\/p\u003e \u003cp\u003eH. Origin of the Drug Stimulus and Sensory Mediation 254\u003c\/p\u003e \u003cp\u003eI. Acquired Differences in Drug Sensitivity 255\u003c\/p\u003e \u003cp\u003eJ. Pharmacological Specificity 258\u003c\/p\u003e \u003cp\u003eK. Phytocannabinoids and Metabolites 260\u003c\/p\u003e \u003cp\u003eL. Endocannabinoid Ligands and the ECS 262\u003c\/p\u003e \u003cp\u003eM. ECS Interactions with Other Signaling Systems 265\u003c\/p\u003e \u003cp\u003eN. Conclusions\/Summary 266\u003c\/p\u003e \u003cp\u003eO. Addendum 268\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9. Discriminative Stimulus Properties of Receptor Antagonists 287\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eJoseph H. Porter\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eA. Introduction 288\u003c\/p\u003e \u003cp\u003eB. Adrenoceptor Antagonists 289\u003c\/p\u003e \u003cp\u003eC. Antihistamines 292\u003c\/p\u003e \u003cp\u003eD. Atypical Antipsychotic Drugs 294\u003c\/p\u003e \u003cp\u003eE. Benzodiazepine Antagonists 299\u003c\/p\u003e \u003cp\u003eF. Cannabinoid Antagonists 299\u003c\/p\u003e \u003cp\u003eG. Cholinergic Antagonists 301\u003c\/p\u003e \u003cp\u003eH. Dopamine Antagonists 302\u003c\/p\u003e \u003cp\u003eI. GABAergic Antagonists 305\u003c\/p\u003e \u003cp\u003eJ. Opiate Antagonists 306\u003c\/p\u003e \u003cp\u003eK. Serotonergic Anatagonists 310\u003c\/p\u003e \u003cp\u003eL. Summary 312\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10. The Discrimination of Drug Mixtures 323\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eIan P. Stolerman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eA. Introduction 324\u003c\/p\u003e \u003cp\u003eB. Functional Models for the Discriminative Effects of Drug Mixtures 326\u003c\/p\u003e \u003cp\u003eC. Initial Studies: Mixtures of Nicotine plus Midazolam 328\u003c\/p\u003e \u003cp\u003eD. Characteristics of Diverse Drug Discriminations 329\u003c\/p\u003e \u003cp\u003eE. Role of Training Doses 334\u003c\/p\u003e \u003cp\u003eF. Variations in Functional Relationships: The Role of Training Paradigm 336\u003c\/p\u003e \u003cp\u003eG. Antagonism of Mixture Cues and Training with Agonists plus Antagonists 342\u003c\/p\u003e \u003cp\u003eH. Associative Processes 345\u003c\/p\u003e \u003cp\u003eI. Investigations on the Ethanol Cue as a Compound Stimulus 348\u003c\/p\u003e \u003cp\u003eJ. Discussion 351\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11. Making the Right Choice: Lessons from Drug Discrimination for Research on Drug Reinforcement and Drug Self-Administration 361\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eS. Stevens Negus and Matthew L. Banks\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eA. Operant Conditioning to Study the Stimulus Properties of Drugs 362\u003c\/p\u003e \u003cp\u003eB. Choice Procedures in Studies of Drug Reinforcement: Lessons from Drug Discrimination 371\u003c\/p\u003e \u003cp\u003eC. Summary 380\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12. Inhalant Drug Discrimination Studies in Phesus Monkeys: Drug Dependence and Withdrawal 417\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eJun-Xu Li, Lisa R. Gerak, and Charles P. France\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eA. Introduction 417\u003c\/p\u003e \u003cp\u003eB. Some Factors Impacting the Discriminative Stimulus Effects of Drugs 418\u003c\/p\u003e \u003cp\u003eC. Drug Interactions: Acute Dosing 420\u003c\/p\u003e \u003cp\u003eD. Drug Interactions: Chronic Dosing 423\u003c\/p\u003e \u003cp\u003eE. Summary and Conclusions 427\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14. Human Drug Discrimination: Methodological Considerations and Application to Elucidating the Neuropharmacology of Amphetamines 431\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eCraig R. Rush, Andrea R. Vansickel, and William W. Stoops\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eA. Introduction 432\u003c\/p\u003e \u003cp\u003eB. Methodological Issues to Consider when Designing and Conducting a Human Drug Discrimination Experiment 433\u003c\/p\u003e \u003cp\u003eC. Using Human Drug Discrimination to Elucidate the Neuropharmacology of Amphetamines 444\u003c\/p\u003e \u003cp\u003eD. The Future of Human Drug Discrimination 449\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15. Nicotine Discrimination in Humans 463\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eKenneth A. Perkins\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eA. Introduction 464\u003c\/p\u003e \u003cp\u003eB. Basic Methods of Nicotine Discrimination Research in Humans 465\u003c\/p\u003e \u003cp\u003eC. Basic Parameters of Nicotine Discrimination 468\u003c\/p\u003e \u003cp\u003eD. Individual Differences and Moderators of Nicotine Discrimination 473\u003c\/p\u003e \u003cp\u003eE. Conclusions 477\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16. Drug Discrimination: A Perspective 483\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eThe late Francis C. Colpaert\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eA. State Dependence and Drug Discrimination 484\u003c\/p\u003e \u003cp\u003eB. Drug Discrimination in Receptor Pharmacology 484\u003c\/p\u003e \u003cp\u003eC. Drug Discrimination and Subjective Drug Effects 485\u003c\/p\u003e \u003cp\u003eD. New Concepts of Opiate Tolerance, Signal Processing, Pain, and Analgesia 486\u003c\/p\u003e \u003cp\u003eE. Drug Discrimination: An Elementary Particle of Behavior and More 488\u003c\/p\u003e \u003cp\u003eF. When Dependent Variables Chose Their Pharmacology 491\u003c\/p\u003e \u003cp\u003eG. Two Further Mysteries 491\u003c\/p\u003e \u003cp\u003eH. Epilogue 492\u003c\/p\u003e \u003cp\u003e\u003cb\u003eIndex 497\u003c\/b\u003e\u003c\/p\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":49402331660631,"sku":"9780470433522","price":134.06,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780470433522.jpg?v=1730480090","url":"https:\/\/bookcurl.com\/products\/drug-discrimination-9780470433522","provider":"Book Curl","version":"1.0","type":"link"}